You are currently viewing the editor's summary.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Interrupting inflammation in atopic dermatitis
The alarmin cytokine IL-33 is implicated in a variety of conditions, including atopy, and is an emerging therapeutic target. Chen et al. report a clinical trial of a single dose of an anti–IL-33 antibody (etokimab) in adults with moderate to severe atopic dermatitis. The trial design included a placebo condition and assessment of skin immune responses to challenges with house dust mite. Clinically, anti–IL-33 was well tolerated and reduced peripheral eosinophils and symptoms of atopic dermatitis. Blocking IL-33 interfered with neutrophil recruitment. These results reveal human immunobiology and demonstrate that anti–IL-33 is a promising therapeutic for atopic dermatitis.
- Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works
This is an article distributed under the terms of the Science Journals Default License.
